Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, …
Maxim Group’s healthcare analyst Jason Kolbert weighed in today with research reports on the Canadian urology company Sophiris Bio Inc (NASDAQ:SPHS), Israeli stem cell company Pluristem Therapeutics Inc. (NASDAQ:PSTI), …
Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares rose 8.
In a research report published Tuesday, MLV analyst Vernon Bernardino maintained a Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a price target …
